French scientist Didier Raoult tries to silence whistle-blower over discredited COVID-19 hydroxychloroquine claims
French microbiologist Dr. Didier Raoult, who published a now-discredited paper in March 2020 claiming that hydroxychloroquine was effective at treating COVID-19, has threatened legal action against scientists criticizing his research. These include Elizabeth Bik, the whistleblower who first exposed methodological inconsistencies in Raoult’s research, and Boris Barbour, who runs the not-for-profit website
Pubpeer allowing scientists to review each other’s work.
Dr. Didier Raoult (AP Photo/Christophe Ena)
On May 18, an open letter supporting Bik against Raoult’s attack titled “Scientists stand up to protect academic whistleblowers and post-publication peer review” was published. It has since been signed by over 1,000 scientists across the globe, working across multiple disciplines.
VALBIOTIS Releases Its 2020 Annual Results
2020 highlights and results
Global strategic partnership with Nestlé Health Science for the development and marketing of TOTUM-63, a plant-based active substance with clinically proven metabolic health benefits in prediabetic subjects.
Launch of REVERSE-IT, a global pivotal Phase II/III clinical trial of TOTUM-63 for reducing Type 2 Diabetes risk factors.
New milestones achieved with TOTUM-070, a plant-based active substance for lowering LDL-cholesterol, a risk factor for cardiovascular disease.
€14.6m in cash as at December 31, 2020.
Post-balance sheet events and outlook
Important milestones are expected to be reached in the development of TOTUM-070 (reduction in blood LDL-cholesterol levels).
Inotrems COVID-19 Phase IIa Clinical Trial Declared National Priority Research by the French Governments Clinical Trial Council financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Inotrem’s COVID-19 Phase IIa Clinical Trial Declared “National Priority Research” by the French Government’s Clinical Trial Council
December 24, 2020 GMT
PARIS (BUSINESS WIRE) Dec 24, 2020
Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway, announces today that its Phase IIa study of nangibotide, the company’s lead product, for the treatment of severe forms of COVID-19 has been declared “National Priority Research” by the French government steering committee for therapeutic clinical trials and other research (CAPNET).
AKTIONÄR-Hot-Stock Abivax: 134 Prozent im Plus – was ist da los? deraktionaer.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from deraktionaer.de Daily Mail and Mail on Sunday newspapers.